Overview

Location [1]
12p13.31
Protein [2]
Alpha-2-macroglobulin
Synonyms [1]
A2MD, S863-7, CPAMD5, FWP007

A2M is altered in 0.08% of all cancers with lung adenocarcinoma, acute myeloid leukemia, cancer of unknown primary, diffuse large B-cell lymphoma, not otherwise specified, and glioblastoma having the greatest prevalence of alterations [3].

A2M GENIE Cases - Top Diseases

The most common alteration in A2M is A2M-ALK Fusion (0.08%) [3].

A2M GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.